Cargando…

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

Adjuvant chemotherapy improves breast cancer survival but is associated with bothersome short- and long-term toxicity. Factors associated with toxicity, especially subacute toxicity up to 2 years following chemotherapy, have not been fully elucidated. The NRG Oncology/NSABP B-30 clinical trial compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henry, N. Lynn, Kim, Sungjin, Hays, Ron D., Diniz, Marcio A., Tighiouart, Mourad, Gresham, Gillian, Luu, Michael, Cecchini, Reena S., Yothers, Greg, Rogatko, André, Ganz, Patricia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675799/ https://www.ncbi.nlm.nih.gov/pubmed/36402796 http://dx.doi.org/10.1038/s41523-022-00489-9

Ejemplares similares

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
por: Calsavara, Vinicius F., et al.
Publicado: (2023)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index
por: Gresham, Gillian, et al.
Publicado: (2020)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
por: Diniz, Márcio A., et al.
Publicado: (2021)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data
por: Calsavara, Vinicius F., et al.
Publicado: (2022)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

On the properties of the toxicity index and its statistical efficiency
por: Razaee, Zahra S., et al.
Publicado: (2020)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Comparison between continuous and discrete doses for model based designs in cancer dose finding
por: Diniz, Márcio Augusto, et al.
Publicado: (2019)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
por: Diniz, Márcio A, et al.
Publicado: (2020)

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Talking numbers: how women and providers use risk scores during and after risk counseling – a qualitative investigation from the NRG Oncology/NSABP DMP-1 study
por: Blakeslee, Sarah B, et al.
Publicado: (2023)

Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2014)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey()
por: Cook, Elise D., et al.
Publicado: (2018)

A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2016)

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding
por: Rogatko, André, et al.
Publicado: (2015)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

The Integrated Web Portal for Escalation with Overdose Control (EWOC)
por: Wang, Haibin, et al.
Publicado: (2013)

Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials
por: Hallemeier, Christopher L., et al.
Publicado: (2023)

Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease
por: Yang, Dehua, et al.
Publicado: (2017)

NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery
por: Chetvertkov, Mikhail, et al.
Publicado: (2020)

caGrid-Enabled caBIG(TM) Silver Level Compatible Head and Neck Cancer Tissue Database System
por: Wang, Haibin, et al.
Publicado: (2010)

NRG-1 talks back to neurons
por: LeBrasseur, Nicole
Publicado: (2003)

NRG1 fusions in breast cancer
por: Howarth, Karen D., et al.
Publicado: (2021)

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
por: Paterson, Alexander H G, et al.
Publicado: (2021)

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
por: Seamon, Leigh G, et al.
Publicado: (2018)

Back signaling by the Nrg-1 intracellular domain
por: Bao, Jianxin, et al.
Publicado: (2003)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
por: Rogatko, Cleo P., et al.
Publicado: (2021)

Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice
por: Spencer, Jarrah R., et al.
Publicado: (2013)

Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology
por: Gensheimer, Michael F., et al.
Publicado: (2020)

NRG Oncology Survey of Monte Carlo Dose Calculation Use in US Proton Therapy Centers
por: Lin, Liyong, et al.
Publicado: (2021)

Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
por: Yom, Sue S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a4c0ardfj6q6p5vr4csihdintg